PCRX Pacira Pharmaceuticals Inc.

+0.1  (+0%)
Previous Close 39.61
Open 39.7
Price To Book 5.42
Market Cap 1632645557
Shares 41,114,217
Volume 290,083
Short Ratio
Av. Daily Volume 595,350

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved October 31, 2011.
Postsurgical pain
Approval announced April 6, 2018.
Post surgical pain

Latest News

  1. Pacira to Report 2018 Financial Results on Thursday February 28, 2019
  2. See what the IHS Markit Score report has to say about Pacira Pharmaceuticals Inc.
  3. 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
  4. Why Pacira (PCRX) Could Beat Earnings Estimates Again
  5. Factors to Know Ahead of Herbalife's (HLF) Q4 Earnings
  6. Pacira Expands EXPAREL Manufacturing Capacity to Meet Growing Demand
  7. Should You Be Concerned About Pacira Pharmaceuticals, Inc.’s (NASDAQ:PCRX) Historical Volatility?
  8. Pacira's Study on Exparel Label Expansion Meets Endpoints
  9. EXPAREL Achieves Statistically Significant Reductions in Opioid Consumption and Pain Scores in Cesarean Section Patients
  10. New Research Coverage Highlights LKQ, Pacira Pharmaceuticals, WellCare Health Plans, Masimo, Workday, and Potbelly — Consolidated Revenues, Company Growth, and Expectations for 2019
  11. Cara (CARA) Up on IDMC's Recommendation to Continue Trial
  12. Pacira Reports Preliminary 2018 Net EXPAREL® Sales of $331 Million
  13. An Intrinsic Calculation For Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Shows It’s 34.81% Undervalued
  14. Pacira Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
  15. New Retrospective Analysis Demonstrates Significant Reductions in Postsurgical Pain and Opioid Requirements with EXPAREL in Cesarean Section Patients
  16. Zacks.com featured highlights include: Abercrombie & Fitch, Pacira Pharmaceuticals, Penumbra, Sprint and Salesforce.com